People have been riding the GLP-1 wave to achieve quick and significant weight loss. But given the drug’s effect on controlling type 2 diabetes, it’s no surprise that DexCom CEO Jake Leach wants to ride that wave as well. DexCom makes continuous glucose monitoring devices (CGMs) that are worn 24/7 by patients. They were initially used for the type 1 population that needed them to know when to take insulin and manage their disease but — as evidence of their efficacy has grown — CGMs are now prescribed for type 2 diabetes patients as well.

“So we’ve kind of been in this business of how do we use the CGMs to optimize pharmaceutical therapies, insulin being the first, [but] there’s opportunities with GLP-1s,” Leach said in a recent interview. “There’s all kinds of opportunities for us to guide therapy for both the physician and the patient to work together to get a better outcome faster.” Read More >